Axa’s iShares Biotechnology ETF IBB Stock Holding History

Axa’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,040	Closed	-$521K	–	1336
2017 Q2	$521K	Buy	+5,040	New	+$496K	﹤0.01%	1049

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Axa's IBB Position: Q3 2017 in Review

Axa sold out of iShares Biotechnology ETF (IBB) in Q3 2017, closing a stake of 5,040 shares — an estimated $521K sold.

Axa first reported a position in IBB in Q2 2017 and held it in 1 quarter. The position peaked at $521K in Q2 2017. 583 funds tracked by Wall St. Rank hold IBB as of Q3 2017.

Axa reported no remaining iShares Biotechnology ETF position as of Q3 2017 after selling out during the quarter.
Axa sold 5,040 iShares Biotechnology ETF shares in Q3 2017, an estimated $521K.
Axa first reported a position in iShares Biotechnology ETF in Q2 2017 and held it in 1 quarter.
Axa's iShares Biotechnology ETF position peaked at $521K in Q2 2017.
583 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2017.

Based on Axa's 13F filing for Q3 2017, filed 13 Nov 2017.